Guggenheim Initiates Coverage On Bicara Therapeutics with Buy Rating, Announces Price Target of $42
Benzinga Newsdesk 5 months ago
NewsPrice TargetInitiationAnalyst Ratings
Guggenheim analyst Brad Canino initiates coverage on Bicara Therapeutics (NASDAQ:BCAX) with a Buy rating and announces Price Target of $42.
Guggenheim analyst Brad Canino initiates coverage on Bicara Therapeutics (NASDAQ:BCAX) with a Buy rating and announces Price Target of $42.